Want to join the conversation?
$NKTR said it published pre-clinical results for NKTR-214, an investigational CD122-biased immune-stimulatory cytokine for the treatment of cancer in Clinical Cancer Research. The new paper documents durable anti-tumor efficacy, safety and immune mechanism of action of NKTR-214 in multiple tumor models.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)